Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
c-Met Inhibitor	NCIT_C143099	[Any small molecule that inhibits the enzymatic activity of the receptor tyrosine kinase c-Met (hepatocyte growth factor receptor; HGFR).]
Crizotinib	NCIT_C74061	[An orally available aminopyridine-based inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) and the c-Met/hepatocyte growth factor receptor (HGFR) with antineoplastic activity. Crizotinib, in an ATP-competitive manner, binds to and inhibits ALK kinase and ALK fusion proteins. In addition, crizotinib inhibits c-Met kinase, and disrupts the c-Met signaling pathway. Altogether, this agent inhibits tumor cell growth. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors.]
ALK Tyrosine Kinase Receptor	NCIT_C27032	[ALK tyrosine kinase receptor (1620 aa, ~176 kDa) is encoded by the human ALK gene. This protein is involved in ligand binding, tyrosine phosphorylation and signal transduction.]
MET Tyrosine Kinase Inhibitor SGX523	NCIT_C74062	[An orally bioavailable small molecule, c-Met inhibitor with potential antineoplastic activity. MET receptor tyrosine kinase inhibitor SGX523 specifically binds to c-Met protein, or hepatocyte growth factor receptor (HGFR), preventing binding of hepatocyte growth factor (HGF) and disrupting the MET signaling pathway; this agent may induce cell death in tumor cells expressing c-Met. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays an important role in tumor cell proliferation, survival, invasion, and metastasis, and in tumor angiogenesis.]
LY6K/VEGFR1/VEGFR2 Multipeptide Vaccine	NCIT_C74056	[A multipeptide vaccine consisting of peptides derived from lymphocyte antigen 6 complex locus K (LY6K) and type I and II vascular endothelial growth factor receptors (VEGFRs) with potential antineoplastic activity. Upon administration, LY6K/VEGFR1/VEGFR2 multipeptide vaccine may elicit an antitumor cytotoxic T-lymphocyte (CTL) immune response against LY6K-expressing tumor cells and/or VEGFR-expressing vascular endothelial cells involved in tumor angiogenesis. LY6K is a tumor-associated antigen (TAA) that occurs singly in glycosylphosphatidyl-inositol (GPI)-linked cell-surface glycoproteins or as three-fold repeated domain in the urokinase-type plasminogen activator receptor; VEGFRs are cell surface receptors that stimulate endothelial cell proliferation, invasion, angiogenesis, and vasculogenesis upon ligand binding and receptor activation.]
Boswellia serrata Extract	NCIT_C49089	[A standardized extract derived from the plant Boswellia serrata of the family Burseraceae with anti-inflammatory activity. Boswellia serrata extract contains terpenoid boswellic acids, which are potent inhibitors of 5-lipoxygenase activity and, so, leukotriene synthesis.]
Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine	NCIT_C74057	[A cell-based cancer vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from malignant glioma cells with potential immunostimulatory and antineoplastic activities. Upon administration, malignant glioma tumor lysate-pulsed autologous dendritic cell vaccine exposes the immune system to undefined malignant glioma tumor-associated antigens (TAAs), which may result in anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against glioma cells and glioma cell lysis.]
Manuka Honey	NCIT_C74058	[A monofloral honey with potential wound repair and antibacterial activities. Manuka honey is produced by bees fed on the flowers of the New Zealand Manuka bush (Leptospermum scoparium). Manuka honey contains a significant higher concentration of the 1,2-dicarbonyl compound methylglyoxal, which may account for its antibacterial activity; this agent may release small amounts of hydrogen peroxide which may also contribute to its antibacterial activity. Manuka honey has been reported to stimulate the formation of new blood capillaries and the growth of fibroblasts and epithelial cells when applied topically to wounds.]
Honey	NCIT_C65859	[A sweet and viscous fluid produced by honey bees from flower nectar and other plant fluids.]
Refametinib	NCIT_C74059	[An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.]
Melanoma of the Ciliary Body and Choroid pT2b TNM Finding v7	NCIT_C88693	[Tumor size category 2 with ciliary body involvement. (from AJCC 7th Ed.)]
Melanoma of the Ciliary Body and Choroid pT2 TNM Finding v7	NCIT_C88691	[Tumor size category 2. (from AJCC 7th Ed.)]
Tremelimumab	NCIT_C49085	[A human IgG2 monoclonal antibody directed against the T-cell receptor protein cytotoxic T-lymphocyte-associated protein 4 (CTLA4). Tremelimumab binds to CTLA4 and blocks the binding of the antigen-presenting cell ligands B7-1 and B7-2 to CTLA4, resulting in inhibition of B7-CTLA4-mediated downregulation of T-cell activation; subsequently, B7-1 or B7-2 may interact with another T-cell surface receptor protein, CD28, resulting in a B7-CD28-mediated T-cell activation unopposed by B7-CTLA4-mediated inhibition.]
Melanoma of the Ciliary Body and Choroid pT2c TNM Finding v7	NCIT_C88694	[Tumor size category 2 without ciliary body involvement but with extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)]
Allogeneic Melanoma Cell-Loaded Dendritic Cell Vaccine	NCIT_C49086
Melanoma of the Ciliary Body and Choroid pT2d TNM Finding v7	NCIT_C88695	[Tumor size category 2 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)]
Recombinant Modified Vaccinia Ankara-5T4 Vaccine	NCIT_C49087	[A cancer vaccine comprised of a recombinant modified vaccinia Ankara (MVA) viral vector encoding the 5T4 fetal oncoprotein (MVA-h5T4). Vaccination with recombinant modified vaccinia Ankara-5T4 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) response against tumor cells expressing 5T4 fetal oncoprotein antigen, resulting in tumor cell lysis. The MVA viral vector, derived from the replication-competent strain Ankara, is a highly attenuated, replication-defective vaccinia strain incapable of virion assembly.]
Bavituximab	NCIT_C49088	[A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.]
Xanthomatous Fibrohistiocytic Cell	NCIT_C49081
Melanoma of the Ciliary Body and Choroid pT1d TNM Finding v7	NCIT_C88690	[Tumor size category 1 with ciliary body involvement and extraocular extension less than or equal to 5 mm in diameter. (from AJCC 7th Ed.)]